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Oxidative stress is now believed to play a crucial role for neurodevelopment disorders such as autism spectrum disorders (ASD) and 
attention deficit hyperactivity disorder (ADHD). To review the most recent literature regarding the role of oxidative stress for the 
pathophysiology of ASD and ADHD, we conducted a systematic search of the relevant literature and further discuss the clinical and 
research implications of this knowledge. A systematic search in PubMed database retrieved 132 articles, of which 33 were included in 
the review. This review found relevant evidence concerning the role of oxidative status in ASD and ADHD, albeit with some contradictory 
findings. In order to overcome the incongruities found, more studies are needed in the study of neurodevelopmental disorders, with 
more thorough study designs and particular attention to the accuracy of the diagnostic tools used for the cases included. 
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INTRODUCTION 
Autism spectrum disorders (ASD) are a heteroge‑
neous group of neurodevelopmental disorders charac‑
terized by impairments in communication and in recip‑
rocal social interaction along with restrictive and re‑
petitive behaviours (American Psychiatric Association, 
2013). Questions regarding the etiopathological mecha‑
nism of this complex disorder remain unanswered ( Lai 
et al., 2014; Happe et al., 2006; Antshel and Russo, 2019). 
Attention deficit hyperactivity disorder (ADHD) is 
a frequent and debilitating disorder diagnosed on the 
basis of persistent and developmentally inappropri‑
ate levels of over activity, inattention and impulsivity 
(American Psychiatric Association, 2013). The preva‑
lence of both disorders has continued to rise for the 
past decades (CDC, 2018; Lai et al., 2014), despite the 
systematic use of DSM‑5 criteria for diagnostic propos‑
es. Although this rise is probably most due to improved 
awareness and recognition, an increase in risk factors 
for both disorders cannot be overruled. 
Evidence suggests that the two disorders are co‑
morbid in a high percentage of cases, with percentages 
of co‑occurrence varying from 28%‑44% (Rommelse et 
al., 2010; Lai et al., 2014; Musser et al., 2014; Oerlemans 
et al., 2015). Clinicians frequently find a high propor‑
tion of siblings of ASD patients who are diagnosed with 
ADHD, and vice versa, which raises the suspicion for 
common aetiological ground for both disorders. 
There are several hypotheses concerning ADHD and 
ASD aetiology, albeit questions regarding some of the 
etiopathological mechanism of these complex disor‑
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ders remain unanswered. The current line of evidence 
suggests that neurobiological, neurochemical and ge‑
netic factors are crucial in the pathogenesis of ASD and 
ADHD. The patient neurocognitive dysfunction, its se‑
verity and pervasiveness into multiple developmental 
areas point to the involvement of a diverse and widely 
distributed group of neuronal systems. 
A number of risk factors have been identified for 
both disorders, but until now none has proven to nec‑
essary or sufficient on its one for the disorder to de‑
velop (Lai et al., 2014; Sciberras et al., 2017). The most 
common factors implied in the epidemiology of neu‑
rodevelopment disorders are familiar traits of the dis‑
order, complications during pregnancy, preterm de‑
livery, male gender and low birth weight (Wang et al., 
2017; Sciberras et al., 2017). Advanced maternal and 
paternal ages were associated with increased risk for 
autism spectrum disorders (Hultman et al., 2011; San‑
din et al., 2012). Additionally, iodine deficiency, even 
at a sub‑clinical level, appear to contribute to an in‑
creased risk for both disorders (Blazewicz et al., 2016; 
Abel et al., 2017). Exposure to environmental pollutants 
and chemicals has also been suggested to increase the 
risk of autism and hyperactivity disorder (Dickerson et 
al., 2015; Tran and Miyake, 2017). 
Oxidative stress markers have been found in autism 
and ADHD, suggesting that increased oxidative stress 
may contribute to the development of the disease. 
A series of primary defences exist to protect against 
free radicals and oxidative damage but may not be 
completely effective in this fight. (Davies, 1995; Dal‑
le‑Donne et al., 2006). Reactive oxygen species (ROS) 
play a fundamental part in human physiological and 
pathophysiological processes. ROS react readily with 
proteins, lipids, carbohydrates and nucleic acids. Over‑
production of ROS induce can alter or even destroy 
cellular function, and human antioxidant defenses are 
not always sufficient to maintain a proper ROS balance 
(Brieger et al., 2012). ROS balance is affected by mito‑
chondrial activity, and electron transport chain alter‑
ations, or respiratory chain alterations lead to disrup‑
tions in the redox balance in the mitochondrial matrix 
(Angelova and Abramov, 2018). 
Due to its high oxygen utilization and generation of 
free‑radicals by‑products, its modest antioxidant de‑
fenses and its rich lipid constitution, the brain is then 
particularly prone to oxidative damage (Halliwell, 2006; 
Ng et al., 2008). Additionally, the brain is also suscep‑
tible to secondary and self‑perpetuating damage from 
oxidative cellular injury or necrosis, via the neurotoxic 
effects of released excitatory amines and iron, and the 
activated inflammatory response (Halliwell, 2006; Ng 
et al., 2008). Oxidative stress may therefore be a plau‑
sible pathogenic candidate for psychiatric disorders 
and play a crucial role for neurodevelopment disorders 
such as ASD and ADHD (Chauhan et al., 2004). 
Several markers of oxidative stress are available, 
including quantification of ROS and molecular prod‑
ucts formed from redox and methylation metabolism, 
pro‑oxidant and lipid peroxidation markers and DNA 
damage markers. Antioxidant pathways markers and 
the availability of antioxidant compounds can also con‑
figure a way to measure the presence of antioxidant de‑
fenses (or the lack of them). 
This review addresses the most recent literature re‑
garding the role of oxidative stress in the pathophysi‑
ology of ASD and ADHD. 
Oxidative stress in neurodevelopmental 
disorders ASD and ADHD
Studies of oxidative stress parameters in ASD and 
ADHD written in English were systematically searched 
with Medline (PubMed, National Center for Biotech‑
nology Information, U.S. National Library of Medicine, 
Bethesda, Maryland), until September 2019. The search 
strategy was to combine free radicals, oxidative stress 
and reactive oxygen species Medical Subject Headings 
(MeSH) terms with keywords describing clinical out‑
comes (“autistic disorder”, “autism spectrum disor‑
ders” (MeSH term introduced in 2016 in PubMed) and 
“attention deficit disorder with hyperactivity”). This 
was supplemented by a thorough search of referenc‑
es of the selected articles. Observational case control 
studies including children or adult patients diagnosed 
with autism spectrum disorders or with attention defi‑
cit hyperactivity disorder were eligible for the review. 
Exclusion criteria were: the studies did not present 
data on included oxidative stress parameters; the re‑
cords were review, editorial or opinion articles; the 
records were animal studies; or the studies were not 
published in English.  
After removal of duplicates, 128 records were as‑
sessed based on title and abstract. The full‑text of 78 of 
these records was retrieved for further assessment. Of 
these, 45 did not met the inclusion criteria for qualita‑
tive analysis. The records retrieved approached either 
the search for oxidative markers in these two popula‑
tions, as well as possible alterations in the antioxidant 
pathways and respective markers. Summary of all arti‑
cles included can be found in Tables I and II. 
ROS, redox and methylation metabolism
In four of the studies included, nitric oxide (NO) was 
measured, two in ASD populations and two in ADHD 
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populations. All of them found NO to be significantly 
increased in cases when compared to controls (Sogut et 
al., 2003; Selek et al., 2008; Ceylan et al., 2010; Lakshmi 
Priya and Geetha, 2011). One study measured NO2 and 
NO3 as surrogate markers to assess the activity of nitric 
oxide synthase (NOS) in a small sample of adults with 
ADHD diagnosis but found no significant differences in 
cases when compared to controls (Kittel‑Schneider et 
al., 2015). However NOS was found to be increased in 
another study regarding ADHD in a paediatric popula‑
tion (Ceylan et al., 2012). 
Reduced glutathione (GSH) was found to be de‑
creased in seven studies regarding ASD patients (James 
et al., 2004: 2006; Al‑Gadani et al., 2009; Lakshmi Priya 
and Geetha, 2011; Rose et al., 2012; Chauhan et al., 2012; 
Hodgson et al., 2014). One recent study measured of 
GSH in ADHD patients, which were significantly high‑
er in patients when compared with controls (Verlaet et 
al., 2019). Glutathione peroxidase (GSH‑Px) was signifi‑
cantly lower in four studies of ASD patients (Yorbik et 
al., 2002; Mostafa et al., 2010; Meguid et al., 2011; Laksh‑
mi Priya and Geetha, 2011), and significantly increased 
Fig.  1. Summary of the paper selection process as recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement.
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Table I: Summary of articles included regarding ASD.


















↑ SOD↓, CAT↑, 
carbonyl
Ranjbar A, 2014 6-12 DSM-IV-TR urine 29/22 Thiol molecules↓, CAT
↑, Fe3+ to 
Fe2+ (uTAC)↓







































Al-Ayadhi L, 2012 3-9 CARS plasma 44/40 SHH↑, BDNF↑








Lakshmi Priya, 2011 4-12 CARS urine 45/50 TBARS
↑, LHP↑, 
4-HNE↑
Meguid NA, 2011 3-10 CARS plasma 20/25 SOD
↓, GSH-Px↓, 
MDA↑




vit A↓, vit C↓,
Mostafa G, 2010 3,5-12 DSM-IV plasma 44/44 F2-ISOP’s
↑, 
GSH-Px↓
El-Ansary A, 2010 3-15 DSM-IV plasma 30/30 MDA↑





Sadjel-Sulkowska E, 2009 5-32 NOT DISCRIBED cerebellar tissue 3/3 8-OHdG=, 3-NT↑











urine 33/29 8-OHdG=, 8-iso-PGF2α↑
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Table II. Summary of articles included regarding ADHD.



























Kittel-Schneider S, 2015 34.3 DSM-IV plasma 14/33 NO2-=, NO3-=
Bulut M, 2013 25.3 DSM-IV plasma 35/29 MDA↑ PON↓, ARES↓
Selek S, 2012 24.7 DSM-IV plasma 50/31 TOS↑, OSI↑ TAS↑
Ceylan M, 2012 7-15 DSM-IVCTRS plasma 35/35
NOS↑, XO↑,  
GST↓, ADA↑ PON-1
↓
Oztop D, 2012 6-12 DSM-IV plasma 30/30 MDA
↓, 8-OHDG↓, 
AOPP=, Thiol= PON-1=
Kawatani M, 2011 10 DSM-IV urine 10/73 Acrolein-lysine↑
Ceylan M, 2010 7-15 DSM-IV plasma 35/35 NO
↑, MDA↑, 
SOD=, GSH-Px↓ CAT=
Selek S, 2008 27.95 DSM-IV blood 20/21 SOD↓, NO↑
ADA: adenosine deaminase; ADHD: attention deficit hyperactivity disorder; AOPP: advanced oxidation protein products; ARES: arylesterase; CAT: catalase activity;  
CTRS: Conners’ Teacher Rating Scale; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders-IV; GSH-Px: Glutathione peroxidase; GST: glutathione S-transferase;  
MDA: malondialdehyde; NO: nitric oxide; NOS: nitric oxide synthase; OSI: oxidative stress index; SOD: superoxide dismutase; PON: paraoxonase; SPON: stimulated 
paraoxonase; TAS: total antioxidative status; TOS: total oxidative status; XO: xanthine oxidase; 8-OHdG: 8-hydroxy-2-deoxyguanosine.























Zoroglu S., 2004 4.7 CARS RBC 27/26 TBARS
↑, SOD↑, 
CAT↓, ADA=, XO↑
Sogut S, 2003 2-12 CARS RBC 27/30 SOD=, GSH-Px
↑, 
TBARS=, NO↑
Yorbik O, 2002 4-12 DSM-IV plasma/RBC 45/41 GSH-Px↓, SOD↓
AB: autism behavior; ADA: adenosine deaminase; ADI-R: autism diagnostic interview – revised; ADOS: autism diagnostic observation scale; ADOS-G: autism diagnostic 
observation scale – generic; ASD: autism spectrum disorder; BA22: Brodmann area 22; BDNF: brain-derived neurotrophic factor; BSID-II: Bayley scales for infant 
development-II; CARS: Childhood autism rating scale; CAT: catalase activity; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders-IV; DSM-IV-TR: Diagnostic and 
Statistical Manual of Mental Disorders-IV text revision; F2-IsoPs: F2-Isoprostanes; GSH: reduced glutathione; GSH-Px: glutathione peroxidase; GSSG: glutathione dissulfide; 
GSSH: glutathione persulfide; LHP: lipid hydroperoxides; MDA: malondialdehyde; NO: nitric oxide; NPBI: non protein-bound iron; PA’s: protein adducts; RBC: red blood cells; 
ROS: reactive oxygen species; SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; SHH: sonic hedgehog; SOD: superoxide dismutase; TBARS: thiobarbituric acid 
reactive substances; uTAC: urinary total antioxidant concentration; VABS: Vineland adaptative behavioural scale; XO: xanthine oxidase; 3-CT: 3-chlorotyrosine;  
3-NT: 3-nitrotyrosine; 4-HNE: 4-hydroxynonenal; 8-OHdG: 8-hydroxy-2-deoxyguanosine; 8-oxo-dG: 8-oxo-deoxyguanosine. 
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in two other studies (Sogut et al., 2003; Al‑Gadani et al., 
2009). One study measured GSH‑Px in ADHD and found 
it to be significantly decreased in those patients (Cey‑
lan et al., 2010). 
Superoxide dismutase (SOD) was assessed in eight 
of the included records, seven regarding ASD patients 
(four of them found it to be decreased (Yorbik et al., 
2002; Meguid et al., 2011; Lakshmi Priya and Geetha, 
2011; Yenkoyan et al., 2018), one didn’t find significant 
differences between groups (Sogut et al., 2003) and two 
found it to be significantly increased (Zoroglu et al., 
2004; Al‑Gadani et al., 2009), and one regarding adult 
ADHD patients, in which SOD was significantly de‑
creased compared to controls (Selek et al., 2008). 
Methylation metabolism was also assessed in ASD 
patients by methionine (James et al., 2004; Melnyk et 
al., 2012; Hodgson et al., 2014), S‑adenosylmethionine 
(SAM) and S‑adenosylhomocysteine (SAH) (James et al., 
2004; 2006: Melnyk et al., 2012; Hodgson et al., 2014), 
adenosine (James et al., 2004; Melnyk et al., 2012), 
homocysteine (James et al., 2004; Melnyk et al., 2012; 
Hodgson et al., 2014), cysteine (James et al., 2004; 2006: 
Melnyk et al., 2012; Hodgson et al., 2014), cysteine 
(Melnyk et al., 2012; Hodgson et al., 2014), cystathi‑
onine (James et al., 2004; Hodgson et al., 2014), GSSG 
(Chauhan et al., 2012; Rose et al., 2012; Hodgson et al., 
2014), homocystine (Hodgson et al., 2014), xanthine ox‑
idase (XO) (Zoroglu et al., 2004) and adenosine deami‑
nase (ADA) (Zoroglu et al., 2004). Globally, all of these 
records point towards a decreased methylation capaci‑
ty in the samples studied. 
Pro‑oxidant/ lipid peroxidation markers
Malondialdehyde (MDA), a common marker for lipid 
peroxidation, was assessed in four studies regarding 
ASD populations, all of them found this marker to be 
significantly increased when compared to controls 
(Chauhan et al., 2004; Al‑Gadani et al., 2009; El‑Ansary 
et al., 2010; Meguid et al., 2011). Similar results were 
found in three articles regarding ADHD patients (Cey‑
lan et al., 2010; Bulut et al., 2013; Verlaet et al., 2019). 
One study found MDA to be significantly decreased in 
ADHD patients when compared to controls (Oztop et al., 
2012). Thiobarbituric acid reactive substances (TBARS) 
were measured in four articles studying ASD patients 
(three found an increased level of this marker (Zoroglu 
et al., 2004; Damodaran and Arumugam, 2011; Laksh‑
mi Priya and Geetha, 2011) and in one no significant 
differences were found between groups (Sogut et al., 
2003). One record included measured total thiol mole‑
cules who were significantly decreased in ASD patients 
when compared to controls (Ranjbar et al., 2014) and 
one study found similar results in ADHD patients and 
controls (Oztop et al., 2012).
Five articles measuring pro‑oxidant and lipid perox‑
idation markers in ASD populations, namely non pro‑
tein‑bound iron (NBPI) (Ciccoli et al., 2013; Pecorelli et al., 
2013), 4‑hydroxynonenal (4‑HNE) (Damodaran and Aru‑
mugam, 2011; Ciccoli et al., 2013; Pecorelli et al., 2013), 
F2‑Isoprostanes (F2‑IsoP’s) (Mostafa et al., 2010; Ciccoli 
et al., 2013) and lipid hydroperoxides (LHP) (Damodaran 
and Arumugam, 2011) were also reviewed. All of them 
showed higher levels of this markers of oxidative stress 
when compared to controls. One record measured total 
antioxidant capacity in ASD patients, who was signifi‑
cantly lower in the patients group (Ranjbar et al., 2014). 
Total oxidative status (TOS) was found to be significant‑
ly increased in two studies including ADHD populations 
(Selek et al., 2012; Guney et al., 2015). These same studies 
measured total antioxidative status (TAS) with conflict‑
ing results. Guney et al. (2015) found TOS to be signifi‑
cantly increased in patients when compared to controls 
levels, while Selek et al. (2012) found TAS in patients to 
be significantly higher than in controls. Acrolein‑lysine 
levels were assessed as a reflexion of lipid peroxidation in 
ADHD cases and were found to be significantly increased 
when compared to controls (Kawatani et al., 2011).
Oxidative protein/DNA damage markers
In ASD patients, three records included measured 
3‑nitrotyrosine (3‑NT) (Sajdel‑Sulkowska et al., 2009; 
Melnyk et al., 2012; Rose et al., 2012) and one record 
measured 3‑chlorotyrosine (3‑CT) (Melnyk et al., 2012), 
all of them found DNA damage markers to be signifi‑
cantly increased compared to controls. Measurement 
of 8‑hydroxy‑2‑deoxyguanosine (8‑OHDG) was found 
to be significantly increased in patients compared with 
their siblings (Yenkoyan et al., 2018), but two previous 
studies in ASD didn’t find significant differences be‑
tween groups (Ming et al., 2005; Sajdel‑Sulkowska et 
al., 2009). Two studies measured 8‑oxo‑deoxyguanosine 
(8‑oxo‑dG) and found significant increases between 
groups (Melnyk et al., 2012; Rose et al., 2012). One study 
found 8‑OHDG to be significant decreased in ADHD pa‑
tients compared to controls (Oztop et al., 2012), while 
one study reports a trend for higher urinary levels of 
8‑OHDG in patients with ADHD (Verlaet et al., 2019).
Antioxidant compounds/antioxidant  
pathways markers
Vitamins A and C were significantly decreased in 
one population of ASD patients (Damodaran and Aru‑
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mugam, 2011), with another record showing a signif‑
icant decrease in vitamin E in ASD patients but fail‑
ing to show significant differences in vitamin C levels 
(Al‑Gadani et al., 2009). 
In ASD patients, catalase activity was shown to be 
decreased intraerythrocitary (Zoroglu et al., 2004) and 
increased in another study (Yenkoyan et al., 2018), and 
one record shows no significant differences in plasma 
between cases and controls (Al‑Gadani et al., 2009). Cat‑
alase activity was also been shown to be increased in 
urine (Ranjbar et al., 2014). In ADHD, one record mea‑
sured catalase activity in plasma of patients, showing 
no significant differences between groups (Ceylan et 
al., 2010). 
One study measured brain‑derived neurotrophic 
factor (BDNF) and sonic hedgehog (SHH), which were 
significant increased in ASD patients (Al‑Ayadhi, 2012). 
Paraoxonase (PON) were significantly decreased in 
two ADHD populations (Ceylan et al., 2012; Bulut et al., 
2013), although one study failed to find any differences 
between cases and controls (Oztop et al., 2012). Aryles‑
terase (ARES) was significantly decreased in one ADHD 
population (Bulut et al., 2013), and no significant dif‑
ferences between cases and controls were found in an‑
other study (Guney et al., 2015). 
In summary, the majority of the studies included 
point towards a pro‑oxidative environment and/or 
a reduced antioxidant capacity in patients with ASD 
and ADHD, resulting in a negative imbalance that sub‑
sequently leads to oxidative damage, confirming the 
authors hypothesis that negative oxidative imbalance 
could be one of the shared factors between these two 
neurodevelopmental disorders.
This review found a considerable amount of evi‑
dence concerning oxidative status in ASD and ADHD. 
However, contradictory findings were detected and 
some of the analyzed studies presented limitations, 
such as inaccurate ratio of cases versus controls, fail‑
ure to pair cases and controls by age, selection of con‑
trols among non‑diagnosed siblings (which constitutes 
a risk, taking in account that some of them may have 
subclinical traits of the disorders) and most important, 
poor assessment and use of diagnostic methods. 
The biologic basis of autism involves gene‑envi‑
ronment interactions during critical development pe‑
riods. Methionine trans methylation and trans sulfu‑
ration pathways are some of the metabolic pathways 
important for the regulation and modulation of cellu‑
lar methylation, DNA synthesis and redox status (Mel‑
nyk et al., 2012). Methionine is an essential amino acid 
that is trans methylated into homocysteine via SAM, 
the major cellular methyl donor. Both methionine and 
SAM were found to be decreased by several authors in 
ASD. Additionally, methylation inhibitors SAH and ade‑
nosine were found to be increased in these patients. To 
date, there are no reports regarding trans methylation 
metabolites in patients with ADHD. 
Both 3‑NT and 3‑CT are stable oxidative post‑trans‑
lational modifications of protein tyrosine residues and 
both were significantly increased in plasma from chil‑
dren with autism, compared to controls. In nuclear and 
mitochondrial DNA, 8‑OHdG is a free radical‑induced 
oxidative lesion that is widely used as a biomarker of 
oxidative damage. There are reports on 8‑OHdG both in 
ADHD patients and ASD patients. As expected, 8‑OHdG 
seem to be increased in plasma of ASD children, but no 
significant levels were found in urine samples. Oztop et 
al. (2012) found significant lower levels of this marker in 
ADHD children, compared to healthy children. The au‑
thors explain that this can be early findings and that, be‑
ing a neurodevelopmental disorder, the levels may rise 
in older populations, as it has been suggested for neuro‑
degenerative disorders. The age factor doesn’t explain, 
however, how some authors found significant higher 
levels of 8‑OHdG in younger populations of ASD patients 
as those studied by Ming et al. (2005) and Sajdel‑Sulkow‑
ska et al. (2009), in which adults were also included.
Another point in favor of the contribution of oxi‑
dative stress to the etiology of neuropsychiatric dis‑
orders of the infancy, as is the case of ASD and ADHD, 
is the depleted level of antioxidant enzymes like SOD 
and GSH‑Px found in several of the articles included 
(Yorbik et al., 2002; Sogut et al., 2003; Selek et al., 2008; 
Al‑Gadani et al., 2009; Mostafa et al., 2010; Ceylan et 
al., 2010; Lakshmi Priya and Geetha, 2011; Meguid et al., 
2011). Contradictory findings, however, are also report‑
ed in both disorders, which make this topic relevant for 
further investigation. 
Some of the studies showed a rise in the antioxida‑
tive defenses in the populations studied, as is the case 
in the study by Al‑Ayadhi et al. (2012) who showed a sig‑
nificant increase of SHH and BDNF in an autistic popu‑
lation. These results could be at first sight considered 
a paradox, since the same studies also report a signifi‑
cant rise in free radicals production. This is however an 
important finding that can be explained as a protective 
mechanism secondary to increase oxidative stress in 
these patients. This was the first time a correlation be‑
tween higher levels of oxygen free radicals and SHH and 
BDNF was reported (Al‑Ayadhi, 2012). The authors fail 
however to explain the reason why they found a posi‑
tive correlation between clinical severity and SHH and 
an absence of correlation between clinical severity and 
levels of oxygen free radicals. On the other hand, how 
the degrees of severity of the disorder were determined 
was not reported, since the cases were selected based 
on a screening test (CARS) and not on an evaluation by 
a child psychiatrist nor gold standard measures like 
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ADIR or ADOS. In fact, the diagnostic methods used are 
one of the major limitations in most of the studies in‑
cluded, since only few used the gold‑standard methods 
for the diagnosis of ASD or ADHD. The methods used to 
determine diagnosis are detailed in Tables I and II. 
Oxidative stress is also evidenced in several ar‑
ticles by the depleted blood levels of enzymatic and 
non‑enzymatic antioxidants. Glutathione, found to 
be decreased in several ASD populations studied, is 
a potent antioxidant which could react and counter‑
act with both ROS and RNS to neutralize them during 
which GSH is converted to GSSG. The regeneration of 
reduced glutathione needs the cooperation of vitamins 
C and E which are the free radical scavenging agents. 
Another powerful antioxidant, considered essential for 
growth and development of young children is vitamin 
A. All of these vitamins where found to decreased in 
at least one study (Al‑Gadani et al., 2009; Damodaran 
and Arumugam, 2011). Whether those deficiencies are 
due to poor nutrient intake, malabsorption problems 
or, in fact, to a higher expenditure of anti‑oxidant com‑
pounds in these particular patients is still not com‑
pletely understood and warrants further investigation. 
ADHD research is still scarce regarding antioxidant 
pathways markers. Only two articles evaluated lipid per‑
oxidation in these population (PON and arylesterase), 
and only one found them to be decreased in a popula‑
tion of adults with ADHD (Bulut et al., 2013). TBARS is the 
end product of lipid peroxidation in the body. It is abun‑
dantly produced from PUFA’s in oxidative stress envi‑
ronments. Pro‑oxidative status measured by lipid perox‑
idation markers, specifically by MDA levels, is the most 
prominent area of research regarding oxidative stress 
in these pathologies. Several articles found increased 
levels of MDA in ASD, with levels in ADHD being more 
controversial, since two authors report increased levels 
(Ceylan et al., 2010; Bulut et al., 2013) while one study 
reported decreased levels of MDA in ADHD patients (Oz‑
top et al., 2012). However, the inclusion of adults in the 
study population may not be the most accurate way to 
establish a link between oxidative stress and ADHD. Be‑
ing a neurodevelopmental disorder, the core symptoms 
emerge in infancy and may attenuate with age. Possible 
adaptive changes may occur through childhood and ad‑
olescence, like neuroplasticity adaptations to consistent 
cognitive behavioural training and learning, so that is 
why pathological links should try to be established be‑
fore or during these periods of development. 
Clinically, ASD and ADHD are quite distinctive dis‑
orders. Nonetheless, symptoms of ADHD are commonly 
seen in clinical practice in children with ASD diagnosis 
and the opposite is also true. Moreover, both disorders 
seem to co‑occur in families and both show heritability 
links. All of those factors have a huge impact on the way 
both disorders are diagnosed – and possible may ac‑
count for some inflated rates of both diagnosis – and ul‑
timately, will have impact on the therapeutic approach 
on these children. Realizing that oxidative stress could 
be behind the pathophysiology of both ASD and ADHD 
could in fact help explain why these two disorders can 
co‑occur in the same patient at such high rates.
CONCLUSIONS
The negative imbalance between antioxidants and 
pro‑oxidants levels in children with autism spectrum 
disorder and attention deficit hyperactivity disorder 
suggest that these disorders are accompanied by in‑
creased oxidative damage. Whether this fact is due to 
increased metabolic stress induced by the disorder or 
can indeed account as a cause for the disorder is still 
not understood. Longitudinal studies may contribute 
to disentangle this circular relationship. Nevertheless, 
the role for oxidative stress in both disorders can very 
well explain the difficulty in finding a single candidate 
gene responsible for ASD and ADHD, so as the rise in 
the co‑occurrence of the disorders. Chronic exposure 
to oxidative stress can result in changes in gene ex‑
pression and protein synthesis, resulting in alteration 
in the synaptic patterns and epigenetic modification of 
gene functions. 
The methods used to measure oxidative status vary 
among the studies included making comparisons of 
study findings difficult to achieve. To be used as diag‑
nostic tools, it is critical that the biomarkers used can 
be stable, able to accumulate to different detectable 
concentrations and correlate to symptoms severity. In 
order to clarify the incongruities found, more studies 
are needed in the study of neurodevelopmental disor‑
ders, with more reliable study designs and particular 
attention to the accuracy of the diagnostic tools used 
for the cases included. The etiology of neurodevelop‑
ment disorders such as ASD and ADHD cannot be fully 
understood unless using a bio‑psycho‑social conceptu‑
alization, integrating a careful and robust clinical ap‑
proach. At the same time, adjusting the accuracy of bi‑
ological markers for these disorders will allow for early 
identification and therapeutic intervention, contribut‑
ing to ameliorate prognosis. 
REFERENCES
Abel MH, Ystrom E, Caspersen IH, Meltzer HM, Aase H, Torheim LE, 
Askeland RB, Reichborn-Kjennerud T, Brantsæter AL (2017) Maternal 
iodine intake and offspring attention-deficit/hyperactivity disorder: re-
sults from a large prospective cohort study. Nutrients 9: pii: E1239. 
Oxidative stress in ASD and ADHD 137Acta Neurobiol Exp 2020, 80: 129–138
Al-Ayadhi LY (2012) Relationship between sonic hedgehog protein, 
brain-derived neurotrophic factor and oxidative stress in autism spec-
trum disorders. Neurochem Res 37: 394–400. 
Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L (2009) Metabolic biomarkers 
related to oxidative stress and antioxidant status in Saudi autistic chil-
dren. Clin Biochem 42: 1032–1040.
Angelova PR, Abramov AY (2018) Role of mitochondrial ROS in the brain: 
from physiology to neurodegeneration. FEBS Lett 592: 692–702. 
Antshel KM, Russo N (2019) Autism spectrum disorders and ADHD: over-
lapping phenomenology, diagnostic issues, and treatment consider-
ations. Curr Psychiatry Rep 21: 34. 
American Psychiatric Association (2013) Diagnostic and statistical manual 
of mental disorders. 5th ed.; Washington, DC. 
Blazewicz A, Makarewicz A, Korona-Glowniak I, Dolliver  W, Kocjan R 
(2016) Iodine in autism spectrum disorders. J Trace Elem Med Biol 
34: 32–37. 
Brieger K, Schiavone S, Miller FJ Jr, Krause KH (2012) Reactive oxygen spe-
cies: from health to disease. Swiss Med Wkly 142: w13659. 
Bulut M, Selek S, Bez Y, Cemal Kaya M, Gunes M, Karababa F, Celik H, Savas 
HA (2013) Lipid peroxidation markers in adult attention deficit hyper-
activity disorder: new findings for oxidative stress. Psychiatry Res 209: 
638–642. 
CDC (2018) Centers for Disease Control and Prevention – National prevention 
of ADHD and treatment. https://www.cdc.gov/ncbddd/adhd/features/
national-prevalence-adhd-and-treatment.html. Accessed 19th July 2019.
Ceylan M, Sener S, Bayraktar AC, Kavutcu M (2010) Oxidative imbalance in 
child and adolescent patients with attention-deficit/hyperactivity disor-
der. Prog Neuropsychopharmacol Biol Psychiatry 34: 1491–1494. 
Ceylan MF, Sener S, Bayraktar AC, Kavutcu M (2012) Changes in oxidative 
stress and cellular immunity serum markers in attention-deficit/hyper-
activity disorder. Psychiatry Clin Neurosci 66: 220–226. 
Chauhan A, Audhya T, Chauhan V (2012) Brain region-specific glutathione 
redox imbalance in autism. Neurochem Res 37: 1681–1689. 
Chauhan A, Chauhan  V, Brown WT, Cohen I (2004) Oxidative stress in 
autism: increased lipid peroxidation and reduced serum levels of 
ceruloplasmin and transferrin – the antioxidant proteins. Life Sci 75: 
2539–2549. 
Ciccoli  L, De Felice C, Paccagnini,E, Leoncini S, Pecorelli A, Signorini C, 
Belmonte G, Guerranti R, Cortelazzo A, Gentile  M, Zollo G, Durand T, 
Valacchi G, Rossi  M, Hayek J (2013) Erythrocyte shape abnormalities, 
membrane oxidative damage, and beta-actin alterations: an unrecog-
nized triad in classical autism. Mediators Inflamm 2013: 432616. 
Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A (2006) Biomark-
ers of oxidative damage in human disease. Clin Chem 52: 601–623. 
Damodaran LP, Arumugam G (2011) Urinary oxidative stress markers in 
children with autism. Redox Rep 16: 216–222. 
Davies KJ (1995) Oxidative stress: the paradox of aerobic life. Biochem Soc 
Symp 61: 1–31. 
Dickerson AS, Rahbar MH, Han I, Bakian AV, Bilder DA, Harrington RA, 
Pettygrove S, Durkin M, Kirby RS, Wingate MS, Tian LH, Zahorodny WM, 
Pearson DA, Moyé LA 3rd, Baio J (2015) Autism spectrum disorder prev-
alence and proximity to industrial facilities releasing arsenic, lead or 
mercury. Sci Total Environ 536: 245–251. 
El-Ansary A, Al-Daihan S, Al-Dbass A, Al-Ayadhi L (2010) Measurement of 
selected ions related to oxidative stress and energy metabolism in Saudi 
autistic children. Clin Biochem 43: 63–70. 
Guney E, Cetin FH, Alisik M, Tunca H, Tas Torun Y, Iseri E, Cayci B, Erel O 
(2015) Attention deficit hyperactivity disorder and oxidative stress: 
A short term follow up study. Psychiatry Res 229: 310–317. 
Halliwell B (2006) Oxidative stress and neurodegeneration: where are we 
now? J Neurochem 97: 1634–1658. 
Happe F, Ronald A, Plomin R (2006) Time to give up on a single explanation 
for autism. Nat Neurosci 9: 1218–1220.
Hodgson NW, Waly MI, Al-Farsi YM, Al-Sharbati MM, Al-Farsi O, Ali A, 
Ouhtit A, Zang T, Zhou ZS, Deth RC (2014) Decreased glutathione and 
elevated hair mercury levels are associated with nutritional deficien-
cy-based autism in Oman. Exp Biol Med 239: 697–706. 
Hultman CM, Sandin S, Levine SZ, Lichtenstein P, Reichenberg A (2011) 
Advancing paternal age and risk of autism: new evidence from a popu-
lation-based study and a meta-analysis of epidemiological studies. Mol 
Psychiatry 16: 1203–1212. 
James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW (2004) Metabolic 
biomarkers of increased oxidative stress and impaired methylation capaci-
ty in children with autism. Am J Clin Nutr 80: 1611–1617. 
James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH (2006) 
Metabolic endophenotype and related genotypes are associated with 
oxidative stress in children with autism. Am J Med Genet B Neuropsychi-
atr Genet 141B: 947–956. 
Kawatani M, Tsukahara H, Mayumi M (2011) Evaluation of oxidative stress 
status in children with pervasive developmental disorder and attention 
deficit hyperactivity disorder using urinary-specific biomarkers. Redox 
Rep 16: 45–46. 
Kittel-Schneider S, Reuss  M, Meyer A, Weber H, Gessner A, Leistner C 
(2015) Multi-level biomarker analysis of nitric oxide synthase isoforms 
in bipolar disorder and adult ADHD. J Psychopharmacol 29: 31–38. 
Lai MC, Lombardo MV, Baron-Cohen S (2014) Autism. Lancet 383: 896–910. 
Lakshmi Priya MD, Geetha A (2011) A biochemical study on the level of 
proteins and their percentage of nitration in the hair and nail of autistic 
children. Clin Chim Acta 412: 1036–1042. 
Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A (2011) Evaluation of ox-
idative stress in autism: defective antioxidant enzymes and increased 
lipid peroxidation. Biol Trace Elem Res 143: 58–65. 
Melnyk S, Fuchs GJ, Schulz E, Lopez M, Kahler SG, Fussell JJ (2012) Metabol-
ic imbalance associated with methylation dysregulation and oxidative 
damage in children with autism. J Autism Dev Disord 42: 367–377. 
Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC 
(2005) Increased excretion of a lipid peroxidation biomarker in autism. 
Prostaglandins Leukot Essent Fatty Acids 73: 379–384. 
Mostafa GA, El-Hadidi ES, Hewedi DH, Abdou MM (2010) Oxidative stress 
in Egyptian children with autism: relation to autoimmunity. J Neuroim-
munol 219: 114–118. 
Musser ED, Hawkey E, Kachan-Liu SS, Lees P, Roullet JB, Goddard K (2014) 
Shared familial transmission of autism spectrum and attention-deficit/
hyperactivity disorders. J Child Psychol Psychiatry 557: 819–827. 
Ng F, Berk M, Dean O, Bush AI (2008) Oxidative stress in psychiatric dis-
orders: evidence base and therapeutic implications. Int J Neuropsycho-
pharmacol 11: 851–876.
Oerlemans AM, Hartman CA, De Bruijn YG, Van Steijn DJ, Franke B, 
Buitelaar JK (2015) Simplex and multiplex stratification in ASD and ADHD 
families: a promising approach for identifying overlapping and unique 
underpinnings of ASD and ADHD? J Autism Dev Disord 45: 645–657. 
Oztop, D, Altun, H, Baskol, G, Ozsoy S (2012) Oxidative stress in children 
with attention deficit hyperactivity disorder. Clin Biochem 45: 745–748. 
Pecorelli A, Leoncini S, De Felice C, Signorini C, Cerrone C, Valacchi G (2013) 
Non-protein-bound iron and 4-hydroxynonenal protein adducts in clas-
sic autism. Brain Dev 35: 146–154. 
Ranjbar A, Rashedi  V, Rezaei  M (2014) Comparison of urinary oxida-
tive biomarkers in Iranian children with autism. Res Dev Disabil 35: 
2751–2755. 
Rommelse NN, Franke B, Geurts HM, Hartman CA, Buitelaar JK (2010) 
Shared heritability of attention-deficit/hyperactivity disorder and au-
tism spectrum disorder. Eur Child Adolesc Psychiatry 19: 281–295. 
Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE (2012) Evidence of oxi-
dative damage and inflammation associated with low glutathione redox 
status in the autism brain. Transl Psychiatry 2: e134. 
Sajdel-Sulkowska EM, Xu M, Koibuchi N (2009) Increase in cerebellar neuro-
trophin-3 and oxidative stress markers in autism. Cerebellum 8: 366–372. 
Sandin S, Hultman CM, Kolevzon A, Gross R, MacCabe JH, Reichenberg A (2012) 
Advancing maternal age is associated with increasing risk for autism: a re-
view and meta-analysis. J Am Acad Child Adolesc Psychiatry 51: 477–486. 
138 Sa-Carneiro et al. Acta Neurobiol Exp 2020, 80: 129–138
Sciberras E, Mulraney M, Silva D, Coghill D (2017) Prenatal risk factors and the 
etiology of ADHD – review of existing evidence. Curr Psychiatry Rep 19: 1. 
Selek S, Bulut M, Ocak AR, Kalenderoglu A, Savas HA (2012) Evaluation of 
total oxidative status in adult attention deficit hyperactivity disorder and 
its diagnostic implications. J Psychiatr Res 46: 451–455. 
Selek S, Savas HA, Gergerlioglu HS, Bulut M, Yilmaz HR (2008) Oxidative 
imbalance in adult attention deficit/hyperactivity disorder. Biol Psychol 
79: 256–259. 
Sogut S, Zoroglu SS, Ozyurt, H, Yilmaz, H. R, Ozugurlu, F, Sivasli, E, Yetkin O, 
Yanik M, Tutkun, Savaş HA, Tarakçioğlu M, Akyolet O (2003) Changes in 
nitric oxide levels and antioxidant enzyme activities may have a role in 
the pathophysiological mechanisms involved in autism. Clin Chim Acta 
331: 111–117. 
Tran NQV, Miyake K (2017) Neurodevelopmental disorders and environ-
mental toxicants: epigenetics as an underlying mechanism. Int J Genom-
ics 2017: 7526592. 
Verlaet AAJ, Breynaert A, Ceulemans B, De Bruyne T, Fransen E, Pieters L, 
Savelkoul HFJ, Hermans N (2019) Oxidative stress and immune aberran-
cies in attention-deficit/hyperactivity disorder (ADHD): a  case-control 
comparison. Eur Child Adolesc Psychiatry 28: 719–729. 
Wang C, Geng H, Liu W, Zhang G (2017) Prenatal, perinatal, and postnatal 
factors associated with autism: a meta-analysis. Medicine 96: e6696. 
Yenkoyan K, Harutyunyan H, Harutyunyan A (2018) A certain role of SOD/
CAT imbalance in pathogenesis of autism spectrum disorders. Free 
Radic Biol Med 123: 85–95. 
Yorbik O, Sayal A, Akay C, Akbiyik D I, Sohmen T (2002) Investigation of 
antioxidant enzymes in children with autistic disorder. Prostaglandins 
Leukot Essent Fatty Acids 67: 341–343. 
Zoroglu S S, Armutcu F, Ozen S, Gurel A, Sivasli E, Yetkin O, Meram I (2004) 
Increased oxidative stress and altered activities of erythrocyte free radi-
cal scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci 
254: 143–147. 
